Dostál V, Libusová L
Department of Cell Biology, Faculty of Science, Charles University in Prague, Viničná 7, 128 43, Prague 2, Czech Republic.
Protoplasma. 2014 Sep;251(5):991-1005. doi: 10.1007/s00709-014-0633-0. Epub 2014 Mar 21.
Microtubule drugs such as paclitaxel, colchicine, vinblastine, trifluralin, or oryzalin form a chemically diverse group that has been reinforced by a large number of novel compounds over time. They all share the ability to change microtubule properties. The profound effects of disrupted microtubule systems on cell physiology can be used in research as well as anticancer treatment and agricultural weed control. The activity of microtubule drugs generally depends on their binding to α- and β-tubulin subunits. The microtubule drugs are often effective only in certain taxonomic groups, while other organisms remain resistant. Available information on the molecular basis of this selectivity is summarized. In addition to reviewing published data, we performed sequence data mining, searching for kingdom-specific signatures in plant, animal, fungal, and protozoan tubulin sequences. Our findings clearly correlate with known microtubule drug resistance determinants and add more amino acid positions with a putative effect on drug-tubulin interaction. The issue of microtubule network properties in plant cells producing microtubule drugs is also addressed.
微管药物,如紫杉醇、秋水仙碱、长春碱、氟乐灵或氨磺乐灵,构成了一个化学性质多样的药物组,随着时间的推移,大量新型化合物不断丰富这一组药物。它们都具有改变微管特性的能力。微管系统紊乱对细胞生理产生的深远影响可用于研究、抗癌治疗以及农业杂草控制。微管药物的活性通常取决于它们与α-和β-微管蛋白亚基的结合。微管药物往往仅在某些分类群中有效,而其他生物则具有抗性。本文总结了关于这种选择性分子基础的现有信息。除了回顾已发表的数据外,我们还进行了序列数据挖掘,在植物、动物、真菌和原生动物的微管蛋白序列中寻找特定界的特征。我们的研究结果与已知的微管药物抗性决定因素明显相关,并增加了更多可能影响药物与微管蛋白相互作用的氨基酸位置。本文还讨论了产生微管药物的植物细胞中微管网络特性的问题。